| Gene Symbol | NLGN1 |
| Full Name | Neuroligin-1 |
| Aliases | NLGN1PROTEIN |
| Chromosome | 3q26.31 |
| Protein Family | receptor |
| Target Class | Receptor |
| Mechanism of Action | Drugs targeting NLGN1 would modulate synaptic adhesion by either enhancing or blocking the neuroligin-neurexin interaction at the postsynaptic membrane, thereby regulating synapse formation, stabilization, and synaptic transmission. Indirect modulators may enhance GABAergic signaling or vasopressin-mediated pathways that influence neuroligin-dependent synaptic maturation and plasticity. |
| Primary Expression | Cortex, Hippocampus, Prefrontal Cortex, Dentate Gyrus |
| Subcellular Localization | Postsynaptic membrane, excitatory synapses |
| Druggability | Medium (0.45) |
| Clinical Stage | Phase II |
| Pathways | memory consolidation, excitatory synaptic transmission, synaptic plasticity, Synaptic Plasticity, Mtor |
| UniProt ID | Q13404 |
| GeneCards | NLGN1 |
| Human Protein Atlas | NLGN1 |
| Associated Diseases | ALZHEIMER, Alzheimer's Disease, DEMENTIA, NEURODEGENERATION |
| Known Drugs/Compounds | Balovaptan, Arbaclofen, NLGN1-targeting nanobodies, Alpha-neurexin modulators |
| Interactions | PSD95, neurexin, TSC2, TSC1, NLGN2, NRXN1 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Trans-Synaptic Adhesion Molecule Modulation |
| KG Connections | 222 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |